STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced a strategic collaboration with Alida ...
STORM Therapeutics has entered a new collaboration with US‑based AlidaBio to accelerate the development of cancer therapies that target RNA modifications.
Mars-like shock and chemical stress reveal ribonucleoprotein condensates as a key survival mechanism in yeast. Life on Mars, ...
Nucleosomes are barriers to RNA Polymerase II (Pol II) transcribing along gene bodies in eukaryotes. We found that a fragile “tailless nucleosome” could be generated to resolve the Pol II pausing ...
Our results demonstrate that differential connectivity analysis reveals significant transcriptional alterations that are not ...
Morning Overview on MSN
Frozen mammoth discovery shatters what scientists knew about ancient RNA
When scientists sliced into a block of Siberian permafrost and pulled out a woolly mammoth nicknamed Yuka, they expected to ...
Thermo Fisher Scientific Launches Invitrogen™ TaqMan™ Cells-to-CT™ HepatoExpress Kit to Simplify Liver Cell Gene Expression and Help Advance Early-Stage Drug ...
Lymphatic malformations (LMs) are congenital vascular anomalies characterized by abnormal lymphatic development, leading to ...
Findings from a study on the role of exosomal non-coding RNAs (ncRNAs) in the progression of multiple myeloma (MM), with a specific focus on sex-based differences, show that while male and female ...
A genomic atlas of Nematostella vectensis reveals how primitive animals created multiple cell types millions of years ago, ...
Type 2 diabetes doesn’t just raise the risk of heart disease—it physically reshapes the heart itself. Researchers studying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback